Comment je traite ... la leucemie myeloide chronique (LMC).

Algorithms; Antimetabolites, Antineoplastic/therapeutic use; Antineoplastic Agents/therapeutic use; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cytarabine/therapeutic use; Enzyme Inhibitors/therapeutic use; Fusion Proteins, bcr-abl/antagonists & inhibitors; Hematopoietic Stem Cell Transplantation; Humans; Interferon-alpha/therapeutic use; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/therapy; Piperazines/therapeutic use; Protein-Tyrosine Kinases/antagonists & inhibitors; Pyrimidines/therapeutic use

Abstract :

[en] This review article describes the identification of the tyrosine kinase BCR/ABL as the hallmark of chronic myeloid leukemias (CML) as well as the development of a specific inhibitor of this tyrosine kinase, the STI571 (Glivec, imatinib mesylate). The authors discuss the results of a phase I and three phase II trials reporting the efficacy of STI571 as treatment for CML patients and propose two simplified algorithms that may help to guide decision-making for the individual patient.

Disciplines :

Hematology

Author, co-author :

Hafraoui, Kaoutar ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique

Humblet-Baron, Stéphanie ; Centre Hospitalier Universitaire de Liège - CHU > Pédiatrie CHR

Baron, Frédéric ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique

Beguin, Yves ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique

Fillet, Georges ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique

Language :

French

Title :

Comment je traite ... la leucemie myeloide chronique (LMC).

Alternative titles :

[en] How I treat...chronic myeloid leukemia

Publication date :

2003

Journal title :

Revue Médicale de Liège

ISSN :

0370-629X

eISSN :

2566-1566

Publisher :

Université de Liège. Revue Médicale de Liège, Liège, Belgium

Volume :

Issue :

Pages :

7-12

Peer reviewed :

Peer reviewed

Available on ORBi :

since 23 March 2009

Statistics

Number of views

400 (7 by ULiège)

Number of downloads

1081 (10 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenAlex citations

Bibliography

Sawyers CL.- Chronic myeloid leukemia. New Engl J Med, 1999, 340, 1330-1340.
Talpaz M, Silver RT, Druker BJ, et al.- Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood, 2002, 99, 1928-1937.
Sawyers CL, Hochhaus A, Feldman E, et al.- Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood, 2002, 99, 3530-3539.
Baron F, Turhan AG, Giron-Michel J, et al.- Leukemic target susceptibility to natural killer cytotoxicity: relationship with BCR-ABL expression. Blood, 2002, 99, 2107-2113.
Faderl S, Talpaz M, Estrov Z, et al.- The biology of chronic myeloid leukemia. New Engl J Med, 1999, 341, 164-172.
Deininger MW, Goldman JM, Melo JV.- The molecular biology of chronic myeloid leukemia. Blood, 2000; 96, 3343-3356.
Issaad C, Ahmed M, Novault S, et al.- Biological effects induced by variable levels of BCR-ABL protein in the pluripotent hematopoietic cell line UT-7. Leukemia, 2000, 14, 662-670.
Baron F, Beguin Y.- Adoptive immunotherapy with donor lymphocyte infusions after allogeneic HPC transplantation. Transfusion, 2000, 40, 468-476.
Gratwohl A, Hermans J, Goldman JM, et al.- Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Lancet, 1998, 352, 1087-1092.
Storb RF, Champlin R, Riddell SR, et al.- Non-myeloablative transplants for malignant disease. Hematology (Am Soc Hematol Educ Program), 2001, 375-391.
Baron F, Beguin Y.- Nonmyeloablative allogeneic hematopoietic stem cell transplantation. J Hematother Stem Cell Res, 2002, 11, 243-263.
Beguin Y, Baron F.- Minitransplants: allogeneic stem cell transplantation with reduced toxicity. Acta Clin Belg, 2002.
Barrett AJ, Childs R.- Non-myeloablative stem cell transplants. Br J Haematol, 2000, 111, 6-17.
Baron F, Baudoux E, Frere P, et al.- Nonmyeloablative Stem Cell Transplantation with CD8-Depleted or CD34-Selected Peripheral Blood Stem Cells. J Hematother Stem Cell Res, 2002, 11, 301-314.
Guilhot F, Chastang C, Michallet M, et al.- Interferon alpha-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. New Engl J Med, 1997, 337, 223-229.
Druker BJ, Lydon NB.- Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest, 2000, 105, 3-7.
Druker BJ, Tamura S, Buchdunger E, et al.- Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of BCR-ABL positive cells. Nat Med, 1996, 2, 561-566.
Deininger MW, Goldman JM, Lydon N, Melo JV.- The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood, 1997, 90, 3691-3698.
Wolff NC, Ilaria RL Jr.- Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571. Blood, 2001, 98, 2808-2816.
Druker BJ, Talpaz M, Resta DJ, et al.- Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med, 2001, 344, 1031-1037.
Druker BJ, Sawyers CL, Kantarjian H, et al.- Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the philadelphia chromosome. New Engl J Med, 2001, 344, 1038-1042.
Kantarjian H, Sawyers C, Hochhaus A, et al.- Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med, 2002; 346, 645-652.
Druker BJ.- STI571 (Gleevec) as a paradigm for cancer therapy. Trends Mol Med, 2002, 8, S14-S18.
Appelbaum FR.- Perspectives on the future of chronic myeloid leukemia treatment. Semin Hematol, 2001, 38, (3 Suppl 8), 35-42.
Goldman JM, Druker BJ.- Chronic myeloid leukemia: current treatment options. Blood, 2001, 98, 2039-2042.